Physician Views: How will US rheumatologists use Regeneron and Sanofi's Kevzara?

Regeneron and Sanofi's IL-6R antibody Kevzara was recently approved by the FDA for the treatment of moderate-to-severe rheumatoid arthritis patients who have had an inadequate response or intolerance to one or more disease modifying anti-rheumatic drugs (DMARDs). Kevzara will be priced (in terms of wholesale acquisition cost or WAC) approximately 30 percent less than the TNF-inhibitors Humira and Enbrel but will compete more directly, at least initially, with Roche's marketed IL-6R antibody Actemra, say key opinion leaders.

To ascertain how this competitive dynamic may play out, with are snap-polling US rheumatologists with the following questions…

Kevzara (sarilumab) has been approved by the FDA for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response or intolerance to one or more disease modifying anti-rheumatic drugs (DMARDs), such as methotrexate (MTX). Kevzara is a human monoclonal antibody that binds to the interleukin-6 receptor (IL-6R), and has been shown to inhibit IL-6R mediated signalling.

How useful is it to have an additional therapy available for the treatment of this condition?

Not useful

Slightly useful

Moderately useful

Very useful

Extremely useful

Key opinion leaders we have interviewed view the efficacy of Kevzara (sarilumab) as being very similar to Actemra (tocilizumab). Actemra can be administered intravenously every four weeks or via subcutaneous injection every week. Kevzara is administered by subcutaneous injection every two weeks. Does this provide Kevzara a meaningful competitive advantage?

No

Slight advantage

Moderate advantage

Significant advantage

Very significant advantage

Based on your experience with Actemra (tocilizumab), how satisfied are you with this product?

Not satisfied – I don't use

Slightly satisfied

Moderately satisfied

Very satisfied

Extremely satisfied

Eliminating cost as a factor, do you think you would be compelled to use Kevzara (sarilumab) as an alternative therapy to Actemra (tocilizumab)?

Not compelled

Slightly compelled

Moderately compelled

Very compelled

Extremely compelled

In what line of therapy would you expect to use Kevzara (sarilumab) most frequently during its first few years on the market?

First-line – i.e. after methotrexate

After two prior therapies

After three prior therapies

After four prior therapies

After five prior therapies

Later

I don't anticipate using Kevzara

Results and related analysis will shortly be published for FirstWord Pharma PLUS subscribers to read, with the opportunity for non-FirstWord Pharma PLUS subscribers to purchase these findings. To be notified when poll results and analysis become available, please click here.

As always, FirstWord would very much like to receive your feedback and suggestions. Note: FirstWord Polls are powered by MedePolls, a fast-turnaround service to conduct instant polls of up to five questions with guaranteed samples that include physicians from dozens of specialties and over 100 markets. To conduct this poll with a different audience, or an entirely different poll, contact us at info@firstwordpharma.com

To read more Physician Views articles, click here.